Fig. 5
From: The m6A reader IGF2BP2 promotes pancreatic cancer progression through the m6A-SLC1A5-mTORC1 axis
Knockout of IGF2BP2 enhances sensitivity of pancreatic cancer cells to radiotherapy and chemotherapy. A. Viability of PANC-1 cells and PaTu 8988 cells with or without IGF2BP2 knockout under 6 Gy radiation therapy and 0 Gy radiation therapy analyzed by the CCK8 assay. B. Representative images from the colony-forming assay and colony number analysis as indicated. C. The effects of 6 Gy radiation treatment on the growth of subcutaneous PANC-1 cells with or without IGF2BP2 knockout xenografts. D. Tumor weight (n = 5) of PANC-1 cells xenografts. E. PANC-1 and PaTu 8988 cells with or without IGF2BP2 knockout were treated with gemcitabine at different concentrations for 48 h, and cell viability was then measured by CCK8 assay. F. Effect of gemcitabine treatment on the growth of subcutaneous PANC-1 cells with or without IGF2BP2 knockout xenografts. G. Tumor weight (n = 5) of PANC-1 cells xenografts